In vivo RNAi: Considerations and examples – a panel presentation

Advancing RNAi experiments towards in vivo studies represents a more rigorous level of testing for nucleic acid therapeutics beyond in vitro, cell-based experiments. Dr Garrett Rettig presents considerations for producing significant knockdown, including: - A suitable model system for testing gene knockdown or phenotypic effect - Route of delivery - Delivery vehicle - Potential for off-target effects Then, Pascal Tétreault presents an example of an in vivo RNAi application, along with a description of the logistics of in vivo experiments conducted in Dr Philippe Sarret's pre-clinical pain lab. The lab uses DsiRNA silencing technology to study the mechanisms of action of G protein-coupled receptors involved in chronic pain in the spinal cord. Both Dr Rettig and Tétreault then discuss challenges for in vivo RNAi experimental setup and take questions from the audience.

All Next generation sequencing videos